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Whole-exome sequencing (WES) has been widely used for analysis of human genetic
diseases, but its value for the pharmacogenomic profiling of individuals is not well
studied. Initially, we performed an in-depth evaluation of the accuracy of WES variant
calling in the pharmacogenes CYP2D6 and CYP2C19 by comparison with MiSeq©R
amplicon sequencing data (n = 36). This analysis revealed that the concordance rate
between WES and MiSeq©R was high, achieving 99.60% for variants that were called
without exceeding the truth-sensitivity threshold (99%), defined during variant quality
score recalibration (VQSR). Beyond this threshold, the proportion of discordant calls
increased markedly. Subsequently, we expanded our findings beyond CYP2D6 and
CYP2C19 to include more genes genotyped by the iPLEX©R ADME PGx Panel in the
subset of twelve samples. WES performed well, agreeing with the genotyping panel
in approximately 99% of the selected pass-filter variant calls. Overall, our results have
demonstrated WES to be a promising approach for pharmacogenomic profiling, with an
estimated error rate of lower than 1%. Quality filters, particularly VQSR, are important
for reducing the number of false variants. Future studies may benefit from examining the
role of WES in the clinical setting for guiding drug therapy.
Keywords: whole-exome sequencing, next-generation amplicon sequencing, multiplexed genotyping panel,
variant quality score recalibration, pharmacogenomic profiling
INTRODUCTION
Whole-exome sequencing (WES) is an increasingly important technology in rare-disease
(Maxmen, 2011) and drug-response genetics (Price et al., 2012). Its core technique comprises
simultaneous capture, enrichment and sequencing of protein-coding and untranslated regions
within the genome (exome). Besides being an eﬀective tool for detecting potentially disease-
causing variant(s), WES can also provide added information on variation in pharmacogenes.
Though WES data has been shown to be highly accurate in previous studies, provided that
appropriate quality ﬁlters are applied (Wang et al., 2013; Linderman et al., 2014; Strom et al., 2014;
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Yi et al., 2014), none of these studies have speciﬁcally explored
the use of WES data for pharmacogenomic proﬁling. Notably,
the accuracy of WES variant calling could be compromised by
the failure of the technology to resolve highly similar genes
(Drögemöller et al., 2013). In particular, sequencing of the
CYP2D6 gene is confounded by the presence of closely related
pseudogenes, CYP2D7 and CYP2D8, such that pre-ampliﬁcation
with long-range PCRs is usually applied to avoid undesired
sequence contamination (Stüven et al., 1996).
The work described in this paper had two primary aims.
First, we carried out an in-depth cross-validation of WES variant
calls in CYP2D6 and CYP2C19 for 36 samples by amplicon
sequencing on the MiSeq R© platform. Then, we expanded our
ﬁndings and evaluated the more general applicability of WES
to pharmacogenomic proﬁling by cross-comparison with the
iPLEX R© ADME PGx Panel. The iPLEX R©ADME PGx panel
uses the MassARRAYR© system (Agena Bioscience, San Diego,
CA, USA) to simultaneously analyze 184 single nucleotide
polymorphisms (SNP), insertions and deletions (INDELs) and 16
copy number variations (CNV) across 36 genes relevant to drug
absorption, distribution, metabolism, and excretion.
MATERIALS AND METHODS
Sample Population
A total of 36 samples were included in this study. These
sequenced samples comprised various research samples referred
to our laboratory for pharmacogenomic investigation. This
study was approved by the Southern Health and Disability
Ethics Committee, New Zealand. Potential participants were
contacted ﬁrst by mail and were required to indicate interest
to participate by ﬁlling in and returning an enclosed form.
Face-to-face interviews were subsequently conducted to
obtain written consent and collect relevant medical history.
The study information sheet and consent form included
procedures for handling of incidental ﬁndings, which would
be followed up in consultation with a clinical geneticist.
DNA was extracted from peripheral blood leukocytes using
a KingFisher Flex Magnetic Particle Processor, as per the
manufacturer’s instructions (Thermo Fisher Scientiﬁc, Waltham,
MA, USA).
High-Throughput Sequencing and
Genotyping
Brieﬂy, for all 36 samples, WES and amplicon sequencing
of the CYP2D6 and CYP2C19 genes were performed. For
WES, paired-end 100-bp sequence reads were generated on
HiSeq R© 2000 and aligned by BWA v0.74 (Li and Durbin,
2009) to the human GRCh37.p13 reference assembly and
processed with SAMtools v0.1.19 (Li et al., 2009) and Picard
v1.96 (http://picard.sourceforge.net). Reads originating from
PCR duplicates were removed with Picard before and after
local realignment around potential indels with GATK v2.7.1
(McKenna et al., 2010). Illumina base quality scores were
recalibrated with GATK in the ﬁnal alignments. Per-sample
identiﬁcation of SNVs and indels was performed using the
HaplotypeCaller algorithm in GATK (v3.3-0). Variants identiﬁed
in 124 unrelated exomes were added to empower genotyping
(GATK GenotypeGVCFs, v3.3-0) and variant quality score
recalibration (VQSR; GATK v3.2-2; DePristo et al., 2011).
Details for processing of amplicon sequencing data are
presented in Supplementary Methods. Raw sequence reads,
which had a mean length of 151 bp, were ﬁrst trimmed
using Trimmomatic v0.30 to remove contaminating adapter-
index sequences (Lohse et al., 2012). Subsequent analysis was
performed using tools available on the Galaxy server (Giardine
et al., 2005; Blankenberg et al., 2010; Goecks et al., 2010).
Trimmed reads were aligned to a custom reference sequence
using BWA-backtrack, duplicates were removed with Picard
v1.56.0, then local base realignment around indels was carried
out with GATK. Finally, variants were called with GATK’sUniﬁed
Genotyper v0.0.6.
A subset of twelve samples were then selected for multiplexed
genotyping by the iPLEX R© ADME PGx Panel (Agena Bioscience,
San Diego, CA, USA). DNAs from these samples were
standardized to 10 ng/µL in a ﬁnal volume of 200 µL. This was
followed by genotyping on the MassARRAYR© System (Agena
Bioscience) using iPLEX R© Gold Biochemistry and Typer v4.0
Software (Agena Bioscience).
Validation of WES Variant Calls in
CYP2D6 and CYP2C19 by Amplicon
Sequencing
Whole-exome sequencing genotype calls having a read depth< 4
or a genotype quality score < 10 were designated “not
evaluable.” GATK deﬁnes genotype quality score as “the Phred-
scaled conﬁdence that the genotype assignment is correct.”
Further, to assess the eﬀectiveness of VQSR at improving
variant calling accuracy, we divided all variants into two sets,
namely those that were called below the 99% truth sensitivity
threshold, also designated “pass-ﬁlter,” and those that were
called with surplus sensitivity (< 99.9%). These values represent
varied levels of variant detection sensitivity relative to a set
of known, true variants; and 99% is a commonly adopted
threshold. Then, because the call-sets comprised a mix of on-
and oﬀ-target variants, those sites that were distant from the
target segments, deﬁned for the TruSeqTM capture kit, were
apt to be poorly covered. Variant calls generated by MiSeq R©
amplicon sequencing were required to have an approximate
read depth of at least 10-fold to be considered suﬃciently
conﬁdent. A false-positive event was deﬁned as the calling
of the alternate allele that was determined to be absent by
MiSeq R© amplicon or follow-up Sanger sequencing. A false-
negative event was deﬁned as the failure to detect the alternate
allele(s).
Cross-Comparison with the iPLEXR©
ADME PGx Panel
Comparison was carried out for variant calls emitted by both
WES and the iPLEX R© ADME PGx Panel. Again, only pass-
ﬁlter WES genotype calls, i.e., having a read depth ≥ 4 and a
genotype quality score ≥ 10, were considered. For the iPLEX R©
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data set, only genotype calls that had a call rate> 85%, indicating
good quality, were selected for validation. The call rates were
determined by the Typer 4 (Agena Bioscience) software, having
assessed spectra quality related to the reported haplotype. Sanger
sequencing was performed to resolve disagreement between the
two platforms.
RESULTS
Validation of CYP2D6 and CYP2C19
Variants by MiSeqR© Amplicon
Sequencing
Whole-exome sequencing was carried out on 36 subjects referred
to our laboratory for PGx analysis. We initially compared the
WES data quality for two key pharmacogenes, CYP2D6 and
CYP2C19, with data generated by an amplicon sequencing assay
we developed on theMiSeq R© (Illumina) platform, for the same 36
samples (Supplementary Methods; per-exon depths of coverage
are presented in Supplementary Figures S1 and S2). A total of
43 variant sites, identiﬁed by WES in the CYP2D6 and CYP2C19
genes, were analyzed (Table 1); of these, 27 were called without
violating the 99% truth-sensitivity threshold. WES variant calling
was highly accurate for the 27 pass-ﬁlter variant sites, achieving
a concordance rate of 99.60% (Table 2). For the 43 variant
sites identiﬁed by WES a total of 943 individual WES genotype
calls were generated across the 36 samples, but 202 calls were
excluded for being of insuﬃcient quality (read depth < 4 or
genotype quality < 10) or because MiSeq R© amplicon sequencing
data were not available. Of the 741 veriﬁable WES genotype
calls, only three calls were found to be discordant with MiSeq R©
data. None were false-positive. Sanger sequencing revealed that
two of the three WES genotype calls that were discordant with
MiSeq R© data (rs17885098 and rs3758581) were actually accurate
(Table 3).
In contrast, when the truth sensitivity threshold was relaxed
to include an additional collection of 16 variant sites (< 99.9%),
the rate of concordance with MiSeq R© data dropped considerably
to 89.11% (Table 2). A total of 1512 calls were generated for
the 43 variant positions; but quality ﬁltering and a dearth
of suﬃciently conﬁdent MiSeq R© data (read depth < 10)
for a number of sites resulted in a ﬁnal comparison set of
1249 WES genotype calls. Of these, 136 mismatches were
identiﬁed, representing a large increase of 133 discordant calls
in relation to the more stringent call-set (truth-sensitivity
threshold < 99%). The majority of these discrepant calls were
false-positives.
Cross-Comparison with the iPLEXR©
ADME PGx Panel
We next sought to examine the concordance between WES data
and a broad PGx proﬁle of 192 nucleotide variations in 36 genes,
generated on a subset of 12 subjects using the iPLEX R© ADME
PGxPanel (Agena Bioscience). Of all 192 polymorphisms covered
by the iPLEX R© ADME PGx panel, 184 are SNPs and INDELs.
Notably, 16 variant sites were not captured by the Nextera
TABLE 1 | All variants identified in CYP2D6 and CYP2C19 by whole-exome
sequencing (WES).
Truth-sensitivity threshold defined by variant quality score recalibration
Below 99% Within the tranche
99–99.9%
CYP2C19 −
Upstream region rs4986894
Exon 1 rs17885098
Exon 2 rs17878459
Intron 2 rs12769205 (∗35)
Exon 5 rs4244285 (∗2)
Intron 5 rs28399511; rs4417205
Exon 7 rs3758580; rs3758581
Intron 7 rs4917623
Intron 8 rs12268020
CYP2D6
Exon 1 rs72549358 (∗28);
rs769258 (∗35); rs1065852
(∗10)
−
Exon 2 rs1081003 rs28371704; rs28371705
Intron 2 − 22:42,525,227A > C
Exon 3 rs1058164; rs78482768
(∗28); rs5030655 (∗6)
−
Intron 3 rs3892097 (∗4) −
Exon 4 − rs139779104;
rs150163869; rs28371713
Intron 4 rs58440431 rs113889384;
rs112568578;
rs111564371
Exon 5 rs5030656 (∗9) −
Exon 6 rs16947 (∗2) −
Intron 6 rs28371725 (∗41) −
Exon 7 − rs61736517; rs1058172
Intron 7 − rs1985842; rs28578778;
rs28371729; rs116917064
Exon 8 rs28371732 −
Exon 9 rs1135840 −
Downstream region rs77845838; rs28371738 22:42,522,498G > A
Off-target variant sites are boldened. Variants are labelled only with the star
alleles that they define. Loss-of-function alleles: CYP2C19∗2, ∗35, CYP2D6∗4, ∗6;
reduced-function alleles: CYP2D6∗9, ∗10, ∗41; functional allele: CYP2D6*2, *35; of
unknown functional consequences: CYP2D6∗28.
exome capture kit; hence, these variants could not be screened
by WES (Table 4). Only pass-ﬁlter WES genotype calls (a read
depth ≥ 4 and a genotype quality score ≥ 10) were considered
for comparison, which resulted in a ﬁnal set of 64 variant sites
that were called by both WES and the iPLEX R© ADME PGx panel
(Table 5).
After eliminating all low-quality (described above) and
missed calls from both panels, 719 genotype calls were
included in our ﬁnal analysis. Of these, eight calls at four
variant sites were found to be discordant with the iPLEX R©
ADME PGx Panel (Table 6), yielding a concordance rate of
98.89%. By Sanger sequencing, we conﬁrmed that all these
discordant calls were correctly genotyped based on the WES
data.
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TABLE 2 | Overview of variant calls generated by WES for CYP2D6 and
CYP2C19, and validation by amplicon sequencing using the
MiSeq R©platform.
Truth-sensitivity threshold
<99% <99.9%
Variant sites 27 43
Total genotype calls
DP < 4 or GQ < 10
No-calls
914
149
29
1476
204
36
Evaluable calls
Missing MiSeq R© data1
794
53
1308
59
Total calls evaluated
Harboring alternate allele(s)
Discordant calls
False-positive(s)2,4
False-negative(s)3,4
Concordance rate
741
201
3
0
1
99.60%
1249
364
136
118
17
89.11%
1Genotype calls generated by amplicon sequencing were required to have a read
depth ≥ 10.
2Where alternate allele was incorrectly called.
3Where reference allele was incorrectly called.
4For discordant calls generated below the truth sensitivity threshold, the
discrepancy was resolved by Sanger sequencing.
Abbreviations: DP, approximate read depth; GQ, genotype quality.
DISCUSSION
Previous studies have established WES to be an eﬀective, high-
throughput variant detection tool that has been successfully
used in the analysis of Mendelian disorders (Wang et al., 2013;
Linderman et al., 2014; Strom et al., 2014; Yi et al., 2014).
This sequencing technique constitutes a potent driving force in
personalized medicine, generating genomic proﬁles that could
also be utilized to tailor pharmacological treatment. Suppose
an individual undergoes WES to aid diagnosis of an unknown
condition, surely the added information on pharmacogenomic
polymorphisms could be interpreted, curated and stored for
guiding future drug therapy? Here we report the results of our
assessment of WES as a potential tool for pharmacogenomic
proﬁling.
We demonstrated that pass-ﬁlterWES variant calls inCYP2D6
andCYP2C19were highly accurate, yielding a near-perfect degree
of concordance with the MiSeq R© amplicon sequencing data,
despite previous concerns that WES is likely to underperform in
genes with closely related homologs (Drögemöller et al., 2013).
The concordance rate decreased substantially to approximately
89%when the truth-sensitivity threshold was raised to 99.9%. The
diﬀerence in concordance rate was rather striking, conﬁrming
previous ﬁndings which have demonstrated the eﬀectiveness of
VQSR at reducing errors in WES data (Yi et al., 2014). In the
clinical setting, a highly accurate call-set is desired, albeit at the
expense of variant-detection sensitivity. We recommend 99%
to be the optimal cut-oﬀ that should minimize the number of
erroneous genotype calls without overly compromising variant
discovery.
Another interesting point is the usability of oﬀ-target variants
(Table 1 and Supplementary Figure S3). For instance, an
important defective CYP2D6 variant, rs3892097 (∗4), is located
outside the capture intervals of the TruSeqTM kit. Nevertheless,
100% agreement was found betweenWES and MiSeq R© amplicon
sequencing data for the variant. Had strict target deﬁnitions
been adopted with no interval extension or “padding,” this
variant would be overlooked. Given the intrinsic mechanism of
TruSeqTM capture, labeling the oﬀ-target sequences as such is
slightly misleading. The kit employs contiguous probes to target
regions of interest; thus capture of overhanging sequences in
fragmented genomic DNA is unavoidable. The current GATK
practice supports a certain extent of ﬂexibility in WES data
processing to encompass variants located within the exon-intron
boundaries. Oﬀ-target variants represent a valuable subset that
gives added information, and this has already been reported by
other investigators (Guo et al., 2012).
We then further analyzed the 20 oﬀ-target sites) with respect
to their approximate read depth and distance from the nearest
TABLE 4 | Variants that are not captured by TruSeqTM kit.
Chromosome position Gene name Variant (rsID) Distance (base)
Chr2:234665659 UGT1A1 rs4124874 3110
Chr2:234676880 UGT1A1 rs55750087 6933
Chr2:234681059 UGT1A1 rs34993780 11112
Chr3:12299435 GSTM1 rs1065411 30851
Chr4:69418747 UGT2B15 rs1902023 15465
Chr4:69961912 UGT2B7 rs7662029 131
Chr7:99270539 CYP3A5 rs776746 87
Chr7:99366316 CYP3A4 rs35599367 41
Chr10:96521657 CYP2C19 rs12248560 656
Chr10:135340567 CYP2E1 rs2070673 150
Chr15:75038220 CYP1A2 rs2069514 2814
Chr15:75041917 CYP1A2 rs762551 4
Chr16:31105353 VKORC1 rs17708472 375
Chr16:31107689 VKORC1 rs9923231 1263
Chr22:19930121 COMT rs737865 551
Chr22:42528382 CYP2D6 rs1080985 1349
 Distance between the variant site and the closest TruSeqTM target.
TABLE 3 | Further examination of three pass-filter discordant genotype calls.
Variant ID, alleles Quality metrics (reference reads,
alternate reads, genotype quality)
WES MiSeq R© amplicon sequencing Sanger sequencing
rs17885098, T/C 18, 0, 54 Homozygous reference Heterozygous variant Homozygous reference
rs3758581, G/A 7, 0, 18 Homozygous reference Heterozygous variant Homozygous reference
rs1135840, G/C 29, 19, 99 Heterozygous variant Homozygous variant Homozygous variant
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TABLE 5 | Variants identified by both WES (“pass-filter”) and the iPLEXR©
ADME PGx Panel.
Gene name Variant(s)
ABCB1 rs1045642; rs2032582; rs1128503; rs3213619
ABCC2 rs717620; rs2273697; rs3740066
ABCG2 rs2231142
COMT rs165599; rs4680
CYP1A1 rs41279188; rs1799814
CYP2A6 rs1801272; rs28399433
CYP2B6 rs8192709; rs12721655; rs3745274
CYP2C19 rs4244285; rs3758581
CYP2C8 rs10509681; rs1058930; rs11572080
CYP2C9 rs1799853; rs1057910
CYP2D6 rs1065852; rs28371725; rs3892097; rs5030655
DPYD rs1801265; rs3918290
GSTP1 rs1138272; rs1695
NAT1 rs4986782
NAT2 rs1208; rs1041983; rs1799929; rs1799930; rs1799931;
rs1801280
SLC15A2 rs2293616; rs1143671; rs1143672
SLC15A3 rs2257212
SLC22A1 rs628031; rs12208357; rs2282143; rs34059508; rs34130495;
rs72552763
SLC22A2 rs316019
SLCO1B1 rs2306283; rs4149056
SLCO1B3 rs4149117; rs7311358
SLCO2B1 rs2306168
SULT1A1 rs1801030; rs9282861
TPMT rs1142345; rs1800460
UGT2B15 rs1902023
UGT2B7 rs7668258
VKORC1 rs7294
target segment. Coverage appeared to range from poor to good
even for variants located at similar distances from TruSeqTM
targets, but was consistently low beyond 100 bases (<150-
fold per 36 samples; Supplementary Figure S3). This suggests
that a maximum distance of 100 bases may be a reasonable
qualifying threshold for invoking an oﬀ-target variant site.
Nonetheless, further analysis will still be required to more
accurately quantify the acceptable deviation from the target
regions that would maintain suﬃcient data quality for variant
discovery; and to ascertain whether call-sets produced using
diﬀerent commercial capture kits, which have varied target
deﬁnitions, could be combined and subjected to the same analysis
pathway.
Using the truth-sensitivity threshold pre-deﬁned above,
we then assessed the broader applicability of WES to
pharmacogenomic proﬁling by cross-comparison with the
iPLEX R© ADME PGx Panel in a subset of 12 samples. The panel
successfully detected 181 single-nucleotide variants per sample
but of these, only 64 were also called by WES without violating
the truth-sensitivity threshold. The majority of the WES-derived
variant calls were consistent with those obtained from the
iPLEX R©ADME PGx Panel, giving a concordance rate of 98.89%.
Eight discordant WES genotype calls were observed and were
subsequently veriﬁed by Sanger sequencing, again conﬁrming
the accuracy of WES variants.
Overall, our results have demonstrated that as a
pharmacogenomic screening tool, WES has an estimated
error rate of lower than 1% for VQSR-ﬁltered variants. This
accuracy of the WES dataset reﬂects the increased reliability and
quality of data now available using longer reads for WES analysis.
The error rate would probably decrease further in the future with
improved analysis software or sequencing workﬂows. Applying
VQSR alone appears unlikely to remove all false-positive variant
calls and additional ﬁlters are required. GATK Best Practice
currently implements the Genotype Reﬁnement workﬂow
to achieve higher data quality. In this pipeline, genotypes with
quality score< 20 are ﬁltered out following VQSR. A recent study
has also found that read depth ≥ 8 and genotype quality ≥ 20 are
good thresholds for removing unreliable genotype calls (Carson
et al., 2014). Our results suggest that less stringent cut-oﬀs
(read depth ≥ 4 and genotype quality ≥ 10) could be adopted
to obtain more genotype calls, at marginal cost to the error
rate.
LIMITATIONS
Remote or non-exonic variants of functional signiﬁcance are
not detectable using the WES technology and this may limit
TABLE 6 | Variant calls found to be discordant between WES and the iPLEXR© ADME PGx Panel.
Variant1,2 Quality metrics (reference reads,
alternate reads, genotype quality)
WES iPLEXR© ADME PGx
Panel
Sanger sequencing
rs1902023 0, 5, 15 Heterozygous variant Homozygous variant Heterozygous variant
rs72552763 6, 4, 99 Heterozygous variant Homozygous variant Heterozygous variant
rs37400663 15, 16, 99
17, 15, 99
Heterozygous variant
Heterozygous variant
Homozygous variant
Homozygous variant
Heterozygous variant
Heterozygous variant
rs992828613 7, 0, 18
8, 0, 24
4, 0, 12
13, 0, 39
Homozygous variant
Homozygous variant
Homozygous variant
Homozygous variant
Heterozygous variant
Heterozygous variant
Heterozygous variant
Heterozygous variant
Homozygous variant
Homozygous variant
Homozygous variant
Homozygous variant
1WES genotype calls were required to have a read depth ≥ 4 and a genotype quality score ≥ 10.
2Genotype calls generated by the iPLEX R© ADME PGx Panel were required to have a call rate > 85%.
3These discordant calls originated from different samples.
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its usefulness (Londin et al., 2015). For instance, −806C > T,
the transcription-enhancing promoter variant of the CYP2C19
gene, was not detected by WES. This variant is common in
the Caucasian population with an allele frequency of 18% (Sim
et al., 2006) and may have an important inﬂuence on clopidogrel
responsiveness (Tiroch et al., 2010). Despite improved accuracy
after applying the VQSR ﬁlter, 20% of the genotype calls from the
WES dataset could not be analyzed due to their poor quality or
low read depth limiting the use of WES as a reliable technique for
clinical application to replace mutation scanning approaches. It
is also worth noting that only about one-third of the 192 iPLEXR©
variants were covered by pass-ﬁlter WES data.
This study did not examine any samples harboring CYP2D6
hybrid alleles, which arise from large-scale CYP2D7 conversion
of the CYP2D6 gene. Consequently, it is not clear how well
BWA-backtrack and the downstream variant caller would resolve
these chimeric sequences, which would contain a large number of
mismatches to the CYP2D6 reference sequence. Because BWA-
backtrack is not designed to tolerate a high error rate (Li and
Durbin, 2009), it is probably not able to process extensively
CYP2D7-converted reads. The presence of hybrid alleles is
therefore likely to adversely aﬀect the quality of CYP2D6 variant
calling on WES data, and other strategies may need to be
employed to circumvent this issue.
Finally, diﬀerent analysis pipelines were employed to process
MiSeq R© amplicon sequencing and WES data. This could have
contributed to the observed discrepancy between the two
sequencing approaches. However, we believe the eﬀect was
unlikely to have been suﬃciently severe to aﬀect the conclusions
that we have drawn.
CONCLUSION
We have demonstrated that WES is a promising tool in
detecting pharmacogenomic variants, even for complex
loci such as the CYP2D6 gene. VQSR is an essential
quality ﬁlter for the removal of likely false variant sites.
Future studies should examine the adoption of WES in
the clinical setting for guiding pharmacological therapy.
For instance, exome analysis could be applied to subjects
in whom CYP2D6 activity has been pharmacokinetically
validated, to determine genotype-phenotype correlation (that
could be occasionally obscured by extensive pseudogene
conversion of the CYP2D6 gene). Various practical aspects
of reporting WES results should be considered, such as
obtaining patient consent for storing and utilizing this piece
of information, translating the WES data into an easy-to-
understand format, and determining the actionability of novel
reported variants.
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